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Available online 1 March 2013Background: Clinical studies provide formalised experience for evidence-based medicine
(EBM). Many people consider a controlled randomised trial (CRT, identical to a randomised
controlled trial RCT) to be the non-plus-ultra design. However, CRTs also have limitations. The
problem is not randomisation itself but informed consent for randomisation and masking of
therapies according to today's legal and ethical standards. We do not want to de-rate CRTs, but
we would like to contribute to the discussion on clinical research methodology.
Situation: Informed consent to a CRT and masking of therapies plainly select patients. The
excellent internal validity of CRTs can be counterbalanced by poor external validity, because
internal and external validity act as antagonists. In a CRT, patients may feel like guinea pigs, this
can decrease compliance, cause protocol violations, reduce self-healing properties, suppress
unspecific therapeutic effects and possibly even modify specific efficacy.
Discussion: A control group (comparative study) is most important for the degree of evidence
achieved by a trial. Study control by detailed protocol and good clinical practice (controlled
study) is second in importance and randomisation and masking is third (thus the sequence CRT
instead of RCT). Controlled non-randomised trials are just as ambitious and detailed as CRTs.
Recommendation: We recommend clinicians and biometricians to take high quality controlled
non-randomised trials into consideration more often. They combine good internal and external
validity, better suit daily medical practice, show better patient compliance and fewer protocol
violations, deliver estimators unbiased by alienated patients, and perhaps provide a clearer
explanation of the achieved success.
© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.Keywords:
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Discussion1. Introduction
1.1. Approaches to evidence based medicine
Clinical studies formalise medical experience for evidence-
based medicine (EBM). Clinical studies range from retrospec-
tive evaluations of medical records over cohort studies, case-
control studies up to controlled, randomised trials. These typestrial; CRT, Controlled
GCP, Good clinical
: +49 731 500 26902.
aus),
C-ND license.of studies are designed for different types of questions and
situations and contribute different degrees of evidence.
Formally, a controlled randomised trial (CRT) is the best
design for a specific and precise hypothesis, especially to
prove efficacy, in settings where most eligible patients give
informed consent, and if the trial can be performed under
suitable conditions. However, CRTs may not be appropriate in
all cases and other designs may be more pertinent [1,2].
1.2. Advocacy
In court, two pleas are necessary to come to a decision:
an advocacy of the prosecutor and one of the lawyer
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controlled, non-randomised studies and invite everybody to
give the opposite advocacy.
1.3. Therapy is a complex procedure
The reasons for therapeutic success (or failure) are often
summarised in three categories:
(1st) self-healing properties of the body and the disease
having already passed the peak when the patient
consulted the doctor,
(2nd) non-specific effects induced by the status as a patient,
i.e. causes of the illness are reduced, the patient
receives sympathy and compassion for his sickness, is
relieved from daily work-load and stress, gains mental
distance from personal problems, is encouraged by
physicians and nursing staff, has trust in the therapist
and is confident in the treatment setting and
(3rd) specific efficacy of physical or pharmaceutical
intervention(s).
Therapeutic success with placebo results from self-
healing and non-specific effects. The effectiveness of placebo
treatment therefore involves many more elements than just
the “placebo effect” itself.
1.4. Information affects the outcome
The placebo effect and many other non-specific treatment
effects largely depend on the information given to the patient
and the trial setting [3–6]. After being informed about a CRT
for consent, patients are often concerned [7,8] and good
evidence suggests that the information given affects expec-
tations and therapeutic outcomes [9,10].
1.5. Estimation of effect sizes
For the best treatment of a patient the efficacy of the
applied medication should be known. However, for both
physicians and patients it is highly interesting to know what
other effects are important for the outcome. The effect of the
applied medication may be less important than other effects,
for example. Controlled comparative studies are necessary to
determine the most important effects on outcome, but
randomisation is not always obligatory.
1.6. Fading of effects
If several CRTs investigate the efficacy of a certainmedicinal
product in similar patients over years, then the effect size
decreases [11]. This fading shows how fragile therapeutic
success can be.
2. Comparative and controlled studies
2.1. Meanings of control
In the context of clinical studies “control” has two
meanings. One is that the study has a control group. We call
this a comparative study. The other meaning is that the studyprocedures are governed by the study protocol and operating
procedures. Some protocols give very few guidelines on the
performance of the study (low control) while others regulate
many details (high control).
2.2. Degree of control
The greatest degree of control is possible in laboratory
experiments. In such experiments, all details are defined and
reported. The experiment is then reproducible in other
laboratories. In clinical studies, different degrees of control
are possible. In highly controlled studies, all measures during
treatment are fixed by protocol and the operating procedures
stipulated, while in studies with little control many measures
are performed as usual in the particular setting. Clinical studies
can vary considerably from laboratory-like studies with a high
degree of control to observational studies without any control
(only observations and documentation are regulated).
2.3. Controlled non-randomised trials (CnRTs)
Often the terms “controlled” and “randomised” arementioned
together in one breath. However, control and randomisation are
completely different procedures. Intensive control is possible
for both randomised and non-randomised trials.
3. Internal and external validity act as antagonists
Internal validity means that the groups to be compared are
not statistically different in any respect except for the treatment
investigated. A randomised, highly-controlled study performed
without major protocol violations has comparable groups and
therefore excellent internal validity. If in such a study the
outcome variable shows a significant difference between groups,
then it can be caused only by the investigated treatment. If all
groups have the same outcome, then an effect of the investigated
treatment cannot be compensated for or hidden by other
influencing variables. Hence, the results of a studywith (perfect)
internal validity can be interpreted. The keyword to describe
internal validity is “laboratory-like conditions”.
3.1. Measures to achieve internal validity
A study protocol regulating all the following aspects in
detail and the performance of the study according to these
regulations ensures internal validity:
• narrow criteria for patient enrolment,
• stratification of admitted patients for the most important
confounders,
• randomisation of patients to treatment groups,
• standardisation of study therapy for each group,
• standardisation of all specific and unspecific measures
of treatment, including the nurse's smile (this is mildly
exaggerated of course),
• standardisation of measurements and a clear and detailed
observation schedule, and
• reliable, objective and valid outcome variable(s).
All these measures – except randomisation – can also
apply to CnRTs.
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Clinical studies should represent daily practice in hospi-
tals, out-patient care and daily life. This is not always the case
in laboratory-like studies. If a study is performed with a
highly selected sample of patients, treated under specific
conditions and with efforts that are not possible for usual
patient care, then the study has poor external validity. Its
results cannot be transferred to daily practice and applied as
standard care. The keyword to describe external validity is
“practice-conditions”.
3.3. Measures to achieve external validity
All patients, to whom the results of the study will be
applied, should have the same chance of being enrolled in the
study. Study procedures should reflect daily life in hospitals
and out-patient care.
3.4. Internal versus external validity
Measures for internal validity and measures for external
validity are often contradictory. It is quite easy to achieve
excellent internal validity and it is quite easy to achieve
excellent external validity, but it is difficult to achieve internal
and external validity in the same study. Internal and external
validity act as antagonists, like the sensitivity and specificity of
a diagnostic procedure. A diagnostic procedure is only useful if
both sensitivity and specificity are acceptable. In an analogous
manner, a really useful study needs internal and external
validity. Ethgen et al. [12] recommend reporting internal as
well as external validity in all publications on controlled trials.
4. Randomisation and informed consent
4.1. Comparability of groups
Groups are comparable if they differ as little as possible
and not more than randomly in structure, treatment (except
the treatment under investigation) and observations (statis-
tical equality of structure, of treatment and of observations).
On evaluation of the study, a statistical test investigates
whether the outcomes differ significantly between groups
(i.e. if the difference in outcome between groups is larger than
can be explained by chance). If, in a study with statistical
equality of structure, treatment and observation, the outcome
between groups is significantly different, this can only be due
to the treatment investigated.
4.2. Effect of randomisation
Randomisation guarantees statistical equality of structure in
the treatment groups. It balances for known and unknown
covariates. However, this holds only if the study can be
performed without dropouts and other major protocol viola-
tions. If variables other than the randomised treatments are
evaluated, e.g. if the question is whether females and males
have the same outcome, then randomisation (between treat-
ment groups) has no effect. Statistical equality of treatment
and of observation may be achieved by intensive control and
monitoring [13].4.3. Disadvantages of randomisation
The problem is not randomisation itself, as introduced to
clinical trials by BradfordHill in 1948, but the informed consent
to randomisation andmasking of therapies according to today's
legal and ethical standards. In a randomised study, doctors
have to declare that they do not know which of the therapies
applied in the study is best for the particular patient. From the
patient's point of view this means: “The doctor has no idea
which therapy is best for me. He's throwing a dice or coin! He
can't be a good doctor. I don't want to be treated by such a
doctor.” Randomisation and masking may appear disparaging
to some – but not all – patients. Therefore, randomisation and
masking disturb the mutual trust between these patients and
the doctor. This reduces the therapeutic success in all groups
and as a consequence the difference in outcome between
groups [14]. Confidence in the therapy and adherence to the
recommendations of the physician improve the patient's
outcome — but are seriously affected by consent in a CRT
[15]. In a non-randomised trial the informed consent must not
cover randomisation and masking and therefore the patient–
doctor-relationship is much less disturbed. Despite sophisti-
cated recruiting strategies, it is becoming more and more
difficult to recruit physicians and patients for CRTs. Often,
many patients will not agree to randomisation. This can lead to
a biased sample of patients giving informed consent and
reduces external validity. The level of evidence achieved by
a CRT depends on patient selection, as shown in simulations
[16].
4.4. Randomisation is not always appropriate
In specific settings, randomisation biases results (in addi-
tion to the problem of informed consent already mentioned).
This holds particularly if therapies cannot be masked and need
the patient's cooperation [17]. Comparative, controlled, non-
randomised trials are more suitable than CRTs for situations
like the ones described in the following examples:
Physiotherapy. Some people like to be physically active;
others do not. Randomisation into groups with andwithout
exercises will lead to the situation where physically active
patients will be active regardless ofwhich group they are in,
while lazy patients will be lazy in all groups.
Training against fear–tension–pain-syndrome during
birth. It iswell known that neonates from first-timemothers
who have participated in a training-course according to
Grantly Dick-Read (1890–1959) have a better Apgar-score
for vitality (Virginia Apgar, 1909–1974) than neonates
whose mothers have not undergone such training. The
reason for this, besides the course itself, might be that the
first-time mothers who participate spontaneously in such a
course aremore health-conscious, smoke less, are happier in
their pregnancy, organise their life better around their
pregnancy, take more care of themselves during pregnancy
etc. than those who don't. A randomised study is practically
impossible, simply because pregnant women will not
consent to randomisation.
Specific diet for patients with rheumatoid arthritis. In a
randomised study to investigate whether a low energy
diet reduces rheumatic inflammation there will be many
130 W. Gaus, R. Muche / Contemporary Clinical Trials 35 (2013) 127–132non-compliant patients, but they will not confess to their
non-compliance.
Anthroposophical medicine. Some people are followers
of Rudolf Steiner (1861–1925) and his naturopathy. In a
study to compare Steiner's anthroposophical medicinewith
scientific medicine anthroposophic patients randomised to
scientific medicine will possibly have poor success because
they are convinced of receiving the wrong therapy. Non-
anthroposophic patients will reject the anthroposophical
procedures because these procedures are strange for them.
5. Performance of controlled, non-randomised trials
5.1. Good clinical practice (GCP)
Today, a well-controlled trial will follow GCP, regardless
of whether it is randomised or not [13]. Please keep in mind
that CnRTs are just as ambitious, sophisticated and elaborate
as CRTs.5.2. Allocating procedures
The most serious problem of a CnRT is to obtain
comparable groups. In a CnRT each patient usually selects
his favoured therapy from those offered by the study. Instead
of patient selection, matched pairs are also possible if there
are few patients and plenty of potential controls. In a
comprehensive cohort study, a patient is randomised if he
agrees to randomisation — otherwise he can select one of the
study groups. Narrow inclusion and exclusion criteria for
patient selection increase comparability of groups. Many
characteristics of the patients must be recorded to identify
the relevant covariates and to enable adjustment for them.
Informed consent is necessary as well, but is easier to obtain,
because the most dissuasive issues, namely randomisation
and masking, are not given.
Protocol violations are formally the same problem in CRTs
and in CnRTs. Both types of studies have to be evaluated by
intention to treat and according to protocol (patients without
major protocol violation). However, it is reasonable to suppose
that patients in CnRTs aremore compliant and adhere better to
the protocol than patients in CRTs, because they are treated per
their choice rather than being forced to follow an unwanted
procedure.5.3. Evaluation
CnRTsmay havemore covariates and diseasemodifiers than
CRTs but even CRTs sometimes require adjustment of covariates
[18]. Statistical methods to adjust covariates and disease
modifiers are (i) multiple regression analysis, (ii) propensity
score-based analysis and (iii) instrumental variable approach.
These are efficient and validmethods to evaluate CnRTs. There is
comprehensive literature about thesemethods [19–21]. Internal
validity of a CnRT needs adjustment of several covariates to
become acceptable. However, it is possible that some covariates
are not recorded or some dependencies not recognized.
Thus internal validity of a CnRT may not be perfect despite
adjustment of covariates.5.4. Study results
CRTs are designed to answer one single question, while
CnRTs often give broader information on therapeutic out-
come because they investigate several predictor variables.
Regression analysis of a CnRT can (i) find out which predictor
variables and which covariates influence the outcome, (ii) give
the sequence of importance of the predictor variables and
covariates, (iii) deliver an estimate of how the outcome is
influenced and how strong the influence is for each predictor
variable and each covariate, (iv) provide information about
which proportion of the variance of the outcome is explained
by the model and (v) indicate how strong the common
influence of all the variables not investigated is (error-term).
Hence, after evaluation of a CnRT with a regression model we
know much more about the outcome than only whether the
investigated therapy is efficient. However, a CRT can also be
evaluated with a regression analysis and deliver the same
information as a CnRT, provided it has the same sample size
and co-variables as the corresponding CnRT. But for a CRT it
will bemore difficult to reach the required sample size than for
a CnRT.
5.5. Reporting
The CONSORT statement is a well-known guideline for
reporting CRTs. Reeves and Gaus [22] give a guideline for
reporting CnRTs.
6. Examples of controlled, non-randomised trials
Serafini et al. [23] reported a CnRT on treatment of rotator
cuff calcific tendonitis. “After local anesthesia was induced,
two 16-gauge needles were inserted into the calcific deposit.
Saline solution was injected through one needle, and the
dissolved calcium was extracted through the other needle.”
This treatment was applied to 219 patients, 68 patients
refused this therapy and were evaluated as controls. After
one year, 5 years and 10 years of shoulder joint function was
assessed by using Constant scores, and pain was assessed by
using a visual analogue scale. We consider this as a good trial
to investigate efficacy of the described therapy with a CnRT.
Randomisation would have led to a non-selection rate of at
least 68 / (219 + 68) = 24% with a serious risk of introduc-
ing bias.
Carlsson et al. [24] compared anthroposophical with
conventional care on quality of life and life satisfaction for
patients with breast cancer. She built 36 matched pairs and
followed them over one year. As already mentioned, such an
investigation would have been impossible as a CRT because
women are either convinced by anthroposophy or not. However,
the observed difference in outcome may have been due to the
different types of therapies or to the different attitudes of the
patients.
Silverman et al. [25] treated obese postmenopausal women
with a hypo-caloric diet (n = 40) or the same dietary scheme
plus walking (n = 46) over 6 months. Outcome variables
were bone mineral density and inflammation parameters.
Again, for this topic, a CnRT might be more appropriate than a
CRT.
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the clinical course of compensated hepatitis C virus-related
cirrhosis. Seventy-two cirrhotic patients treated with interfer-
on werematched to untreated patients of a survey programme
on natural history of cirrhosis. The outcome was the incidence
of clinical complications (hepatocellular carcinoma, ascites,
jaundice, variceal bleeding and encephalopathy) and death.
Although a CRT would have been possible, we consider this
CnRT to be superior with regard to ethics, external validity,
costs, and time until results were available. In view of the
objective and the “hard” outcome variables, the internal
validity of this CnRT is adequate.
7. Conclusion
Randomisation guarantees statistical equality of structure
in the randomised groups if only a few major protocol viola-
tions occur. However, informed consent to randomisation and
masking of therapies is necessary according to today's legal and
ethical standards. The patient's knowledge that his therapy is
selected by a random procedure and that he might receive an
inferior therapy will influence unspecific therapy components
and decrease the patient's compliance, leading tomore protocol
violations. Some patients will not give informed consent and
this may bias the sample of patients investigated.
7.1. Importance of design components
Ranking is difficult and not completely objective in
many situations. But we think that the sequence controlling,
randomisation, and masking is most logical. Without a control
group (controlling) randomisation is not possible. Masking of
therapies only makes sense if therapy is not selected but
randomised. When a study is designed, the decision to have a
group for comparison (controlling) has to be taken first. Then a
decision on randomisation can be taken. Finally, a decision
on masking is possible. At least the sequence controlling,
randomisation, and masking is reasonable.
If a study has no group for comparison, nobody will ask
about randomisation. If the therapy group is selected, nobody
will ask for masking. Hence, we think that the sequence
controlling, randomisation, and masking is also a justifiable
ranking. We are convinced that the sequence CRT is more
appropriate than the sequence RCT.
7.2. Advantages of CnRTs
Comparing a CnRT with a similar CRT (i) it is easier to find
study patients, (ii) external validity can be much better,
(iii) compliance of patients will be better, resulting in fewer
protocol violations, (iv) fewer unconscious processes will
influence the estimation of the investigated effect, (v) results
are easier to generalise and to transfer to daily life, and
(vi) several components of the achieved outcome are explained.
7.3. Disadvantages of CnRTs
Comparing a CnRT with a similar CRT (i) internal validity
may be worse, (ii) sample size should be larger for adjustment
of covariates, (iii)more potential covariates have to be recorded,
and (iv) patients may select one of the therapy-groups lessfrequently than others, which decreases power. (Power de-
pends mostly on the number of patients in the smallest group.)
Researchers planning a CnRT are well advised to try to
compensate for these problems as far as possible.
7.4. Evidence of results
A CRT delivers best evidence for a single specific and
narrow question, in settings where most eligible patients give
informed consent and results are not directly used for daily
practice. However, it can be difficult to apply the result to other
patients [27]. A comparative, controlled, non-randomised trial
might be more suitable for broader problems and the results
may be directly relevant for the daily work of physicians. Even
Sacket et al. [28] say: “EBM is not restricted to randomised
trials and meta-analyses”. Best evidence will be achieved if a
CRT and a CnRT investigating the same question deliver similar
results. This also holds for comprehensive cohort studies
[29,30].
The purpose of this manuscript is not to provide a teaching
book with complete listings of the pros and cons of CRTs and
CnRTs. This is a plea for dialogue, not a final judgment. Inmany
circumstances the decision for randomisation is easy but in
some circumstances this decision is more difficult. This paper
should assist in the latter.
8. Key points
• A group for comparison (comparative study) is most impor-
tant for the validity of results. Strict control of the performance
of the study (controlled trial) is of secondary importance.
Randomisation has rank three. We therefore prefer the
sequence CRT (controlled randomised trial) instead of RCT.
• Randomisation is not the problem, but informed consent
for randomisation and masking. However, today's legal and
ethical standards require informed consent for such trials.
• Internal and external validity act as antagonists.
• Information on randomisation and masking will alienate
some patients. This uncertainty will modify unspecific effects
and may even affect the specific efficacy of treatment.
• Patients will be more compliant in a controlled non-
randomised trial (CnRT) with fewer protocol violations
than in a CRT.
• CnRTs deliver results about several components of the
therapeutic success while a CRT is designed to investigate
efficacy of only one measure.
• CRTs can be characterised as “laboratory-type” trials while
CnRTs are “daily practice-type” trials.References
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